Skip to main content
DataroomDataroom
Data room
  • Welcome to Legit.Health's Data Room
  • Bridge Round
  • Pitch deck
  • Cap Table
  • Product
  • Sales
  • Financials
  • Regulatory
    • Medical Device Certification
    • Quality Management System
    • FDA Strategy
  • Team
  • Trajectory & Recognition
  • Regulatory
  • Medical Device Certification

Medical Device Certification

Regulatory pathway

Current portfolio of regulatory approvals​

🇪🇺European Union
CE marking
MDD Class I (2020) · MDR Class IIa in transition (2026)
✅ Active (MDD) · ⏳ MDR pending
🇬🇧United Kingdom
UKCA Class IIa
Granted 2024 by approved body
✅ Done
🇧🇷Brazil
ANVISA Class II
Full registration obtained Q1 2025
✅ Done
🇺🇸United States · Series A focus
FDA 510(k) Class II
Pre-submission underway. DermaSensor (FDA-cleared 2024) used as predicate device. Expected clearance 2026-27.
🔄 Pre-submission in progress

Certification timeline​

2020
EU MDD Class I obtained
First market entry under European Medical Device Directive
2024
UKCA Class IIa granted
UK market access secured post-Brexit
Q1 2025
ANVISA Brazil Class II
Entry to Latin American largest market
2026 (target)
EU MDR Class IIa
Transition with notified body BSI · PS Consulting partner
2026-27 (target)
FDA 510(k) clearance
Predicate: DermaSensor (cleared 2024) · See FDA Strategy section

Complementary certification: ENS Alto (Spain)​

In addition to the medical device certifications above, Legit.Health holds ENS (Esquema Nacional de Seguridad) at the "Alto" level, the highest tier of Spain's national security framework for information systems.

🇪🇸Spain · Public administration enabler
ENS Alto (Esquema Nacional de Seguridad)
Highest tier of Spain's national security framework for information systems handling public administration data. Required by Spanish public health systems (SESPA, SERMAS, regional CCAA) before contracting digital health solutions. Audited under the Centro Criptológico Nacional (CCN) framework.
✅ Done · Granted 2025
Why ENS Alto matters commercially

Most early-stage healthtech startups don't hold ENS Alto because the certification process is intense (full information security management system, CCN audit, multi-month effort). Holding it pre-Series A unlocks immediately the Spanish public administration procurement channel that competitors without certification cannot access. SESPA (Asturias) was the first deal closed leveraging this enabler.

EU MDR transition​

The MDR (Medical Device Regulation 2017/745) imposes stricter requirements than the previous MDD. Under MDR, our solution is classified as Class IIa (intended for diagnosis support and severity measurement).

Status: Transition in progress with notified body BSI. Consulting partner PS Consulting (Madrid). Expected completion of full MDR Class IIa certification: 2026.

Intended use​

Legit.Health is a clinical decision support system intended for use by healthcare professionals (dermatologists, general practitioners, nurses, and other licensed clinical staff). It provides:

  • Diagnosis support: differential diagnosis for 300+ dermatological conditions
  • Severity measurement: automated scoring on validated scales (PASI, SCORAD, IHS4, AUAS, SALT, GPPGA, AGPPGA)
  • Image quality assurance (DIQA): filtering of non-diagnostic images, enabling teleconsultation at clinical quality

Patients can access the device only when the care provider has granted them access. Direct-to-patient use is not within the intended use.

Previous
Regulatory
Next
Quality Management System
  • Current portfolio of regulatory approvals
  • Certification timeline
  • Complementary certification: ENS Alto (Spain)
  • EU MDR transition
  • Intended use
All the information contained in this data room is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)